News & Events

Apr 12 2017 CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin
Apr 11 2017 Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile
Apr 7 2017 Lakewood-Amedex Advances Novel Bisphosphocin® Nu-8 Compound Based on Encouraging Pre-Clinical Results
Apr 4 2017 Cantex Pharmaceuticals, Inc. Announces Poster Presentation at AACR Annual Meeting 2017
Apr 4 2017 Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
Mar 30 2017 Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members
Mar 30 2017 Enteris to Present at BioCentury’s Future Leaders
Mar 28 2017 Ehave Announces the Appointment of Dave Goyette as Chief Technology Officer
Mar 27 2017 KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
Mar 26 2017 Lakewood-Amedex Announces appointment of Chief Medical Officer and Chief Scientific Officer to enhance drug development and clinical trials program
Mar 22 2017 TapImmune to Participate in Two Upcoming Investor and Industry Conferences
Mar 21 2017 EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme
Mar 17 2017 CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
Mar 17 2017 Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data
Mar 16 2017 KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
Mar 15 2017 Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update
Mar 14 2017 TapImmune Provides Year End 2016 Corporate and Clinical Update
Mar 9 2017 KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
Mar 2 2017 EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme
Mar 2 2017 CorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team
Mar 2 2017 Rebiotix to Present at Two Investor Conferences
Feb 15 2017 TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review
Feb 14 2017 Ehave and MedReleaf Enter Partnership to Optimize the Therapeutic Potential of Medical Cannabis Products
Feb 7 2017 KemPharm to Present at Upcoming Investor Conferences
Feb 7 2017 TapImmune Expands Intellectual Property On PolyStart Platform For Use In Next-Generation T-Cell Vaccines
Feb 6 2017 Rebiotix to Present at BIO CEO & Investor Conference
Feb 6 2017 Galena Biopharma Reports Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
Jan 30 2017 Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
Jan 35 2017 Enteris BioPharma Enters into Agreement with Nordic Bioscience’s KeyBioscience to Develop Orally Delivered Metabolic Peptide
Jan 23 2017 Enteris BioPharma Enters Agreement with Sanofi to Develop Investigational Oral Therapeutic for Type 2 Diabetes
Jan 20 2017 CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group
Jan 11 2017 CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference
Jan 10 2017 Ehave Appoints New Members to its Board of Directors
Jan 9 2017 Aridis Pharmaceuticals Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™
Jan 9 2017 KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain
Jan 5 2017 Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia
Jan 5 2017 CorMedix to Present at Biotech Showcase 2017
Jan 5 2017 Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017
Jan 4 2017 Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection
Jan 4 2017 KemPharm to Present at Biotech Showcase 2017
Jan 4 2017 ContraVir Pharmaceuticals to Present at Biotech Showcase 2017
Jan 3 2017 ContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B
Dec 28 2016 CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017
Dec 28 2016 Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)
Dec 20 2016 KemPharm Granted "Fast Track" Designation for KP201/IR
Dec 19 2016 ContraVir Expands Phase 2a Trial of Tenofovir Exalidex (Formerly CMX157) to Include Doses above 100 mg
Dec 15 2016 ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
Dec 14 2016 KemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD
Dec 14 2016 Multi-Health Systems and Ehave Inc. Enter Partnership to Integrate Psychological Assessments into the Ehave Connect Mental Health Digital Informatics Platform
Dec 14 2016 Galena Biopharma Announces the Phase 2 Clinical Trial of NeuVax™ (nelipepimut-S) in Ductal Carcinoma in Situ (DCIS) is Open for Enrollment and Screening Patients
Dec 13 2016 Medac Pharma, Inc. Appoints Industry Veteran as Vice President of Sales in the U.S.
Dec 12 2016 Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium
Dec 8 2016 ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B
Nov 30 2016 Galena Biopharma to Present Two Posters at the San Antonio Breast Cancer Symposium
Nov 29 2016 Ehave Announces DTC Eligibility of its Common Shares
Nov 22 2016 Ehave to Host First Annual Shareholder Meeting
Nov 21 2016 Ehave Inc. Announces Listing on the OTCQB Under the Trading Symbol EHVVF
Nov 21 2016 Ehave Inc. Appoints Prateek Dwivedi as President and Chief Executive Officer
Nov 15 2016 Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus
Nov 14 2016 Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the Society for Immunotherapy of Cancer Conference 2016
Nov 10 2016 CorMedix Inc. Reports Third Quarter 2016 Financial Results and Provides Business Updates
Nov 9 2016 Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update
Nov 9 2016 KemPharm, Inc. Reports Third Quarter 2016 Results
Nov 3 2016 CureVac Secures an Additional $29.5 Million From Two New Investors
Nov 8 2016 CureVac Receives Broad Patent for RNAntibody® Technology
Nov 8 2016 Aytu BioScience Provides First Fiscal Quarter 2017 Business Update
Nov 7 2016 ContraVir to Present at AASLD's The Liver Meeting® 2016
Nov 7 2016 Aytu BioScience to Provide Fiscal First Quarter 2017 Business Update
Nov 3 2016 KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process
Nov 3 2016 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
Nov 3 2016 Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer
Nov 1 2016 KemPharm, Inc. to Report Third Quarter 2016 Results
Oct 24 2016 ContraVir to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention
Oct 20 2016 Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the American College of Surgeons Clinical Congress 2016
Oct 19 2016 Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
Oct 18 2016 KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology
Oct 17 2016 Data from Rebiotix's Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016
Oct 17 2016 CMX157 Advances Head-to-Head Phase 2a Clinical Study in Hepatitis B Patients with Favorable Recommendation from DSMB
Oct 13 2016 CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread® in Hepatitis B Patients
Oct 11 2016 Rebiotix Receives Patent from the USPTO for Microbiota Restoration Therapy
Oct 11 2016 KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD
Oct 10 2016 Galena Biopharma to Present NeuVax™ (nelipepimut-S) plus Trastuzumab Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
Oct 9 2016 EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology
Oct 3 2016 EnGeneIC's Joint-CEO and Co-Founder, Jennifer MacDiarmid, Ph.D., Recognized in Innovation Category in The Australian Financial Review and Westpac 100 Women of Influence Awards for 2016
Oct 3 2016 ContraVir to Present at the 15th Annual BIO Investor Forum
Oct 3 2016 CorMedix Inc. Appoints Khoso Baluch as Chief Executive Officer
Sept 29 2016 ContraVir to Receive $1.8 Million Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Sept 29 2016 Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy
Sept 29 2016 Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congressr
Sept 27 2016 Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Sept 21 2016 ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors
Sept 20 2016 Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Europe Forum
Sept 20 2016 CorMedix Inc. to Present at Multiple Investor and Industry Conferences
Sept 19 2016 KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
Sept 19 2016 Enteris BioPharma’s “Feasibility to Licensing” Partner, Cara Therapeutics, Advances Peptelligence™-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain
Sept 19 2016 eNeura, Inc. Reports Successful Completion of Post-Market ESPOUSE Study of SpringTMS® Migraine Device
Sept 15 2016 KemPharm, Inc. Provides Corporate and Clinical Update
Sept 14 2016 Aytu BioScience to Present at Two Upcoming Investor Conferences
Sept 14 2016 Galena Biopharma to Present at the 2016 Aegis Growth Conference
Sept 13 2016 Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in Ovarian and Pancreatic Cancer at the Progress in Vaccination Against Cancer (PIVAC) Conference
Sept 12 2016 Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
Sept 12 2016 ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B
Sept 9 2016

Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Sept 8 2016

KemPharm to Present Data at PAINWeek 2016

Sept 7 2016 Marinus Appoints Seth H.Z. Fischer to its Board of Directors
Sept 6 2016 Aytu BioScience to Present at 2016 BioPharm America Conference
Sept 6 2016 Rebiotix to Present at BioCentury's 23rd Annual NewsMakers in the Biotech Industry Conference
Sept 6 2016 ContraVir to Present at Upcoming Investor and Industry Conferences
Sept 1 2016 Aytu BioScience Provides Fiscal Fourth Quarter and Fiscal Year 2016 Business Update
Aug 25 2016 Aytu BioScience to Provide Fiscal Fourth Quarter and Fiscal 2016 Business Update
Aug 22 2016 ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B
Aug 18 2016 Aytu BioScience to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Aug 10 2016 KemPharm, Inc. Reports Second Quarter 2016 Results
Aug 9 2016 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
Aug 9 2016

Galena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update

Aug 2 2016

KemPharm, Inc. to Report Second Quarter 2016 Results

Aug 2 2016 ContraVir Reports Positive Data from Phase 1b Study of CMX157
July 28 2016 Aytu BioScience, Inc. Announces Common Stock Purchase Agreement for up to $10.5 Million
July 28 2016 KemPharm to Present at Canaccord Genuity 36th Annual Growth Conference
July 28 2016

ContraVir Pharmaceuticals to Present at the 2016 Canaccord Genuity Growth Conference

July 26 2016 Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016
July 19 2016 ContraVir Pharmaceuticals to Present at 41st Annual International Herpesvirus Workshop
July 18 2016 ContraVir Expands Scientific Advisory Board to Focus on Seeking Curative Therapy for Hepatitis B
July 14 2016 KemPharm Completes Key Regulatory Meetings with FDA for KP201/IR and KP415
July 14, 2016 Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines
July 13, 2016 Enteris BioPharma Initiates Clinical Program for Tobrate™ (oral tobramycin tablet) in Uncomplicated Urinary Tract Infection
July 8, 2016 Galena Biopharma Announces Pricing of Registered Direct Offering
July 7, 2016 Aytu BioScience Presents Clinical Findings for its MiOXSYS™ System at 32nd Annual Meeting of the European Society of Human Reproduction and Embryology
July 6, 2016 Aytu BioScience Provides Update on Natesto Product Launch
June 28 2016 Aytu BioScience Announces Presentation of Clinical Data Highlighting Efficacy of Natesto™ (Testosterone) Nasal Gel in Men with Seasonal Allergies
June 28 2016 Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
June 22 2016 Aytu BioScience to Execute Reverse Stock Split in Anticipation of Uplisting its Common Stock to a National Exchange
June 22 2016 Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
June 21 2016 ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread® for Treating Hepatitis B
June 16 2016 ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
June 16 2016 Vaccinogen Announces Filing of Oncavert® Patent Application
June 13 2016 FDA Issues Complete Response Letter for Apadaz™ New Drug Application
June 13 2016 Aytu BioScience Announces European Distribution Agreements for Company's MiOXSYS™ System for Male Infertility
June 13 2016 Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
June 13 2016

Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress

June 13 2016 ContraVir Completes Merger with Ciclofilin Pharmaceuticals
June 10 2016 Galena Biopharma Receives Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302
June 9 2016 KemPharm Files NDA Amendment Request with FDA for Apadaz™
June 6 2016 Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
June 6 2016 KemPharm to Present Data from Pharmacokinetic Trial for Investigational Prodrug Benzhydrocodone at the 2016 International Conference on Opioids
June 6 2016 Aytu BioScience Announces Study Initiation and First Patient Dosing in Prostate Cancer Clinical Study with Hybridyne Imaging Technologies for ProstaScint® in Combination with Hybridyne's ProxiScan™ Transrectal Camera
June 2 2016 ContraVir Pharmaceuticals to Present at 2016 Biotechnology Innovation Organization International Convention
June 1 2016 Galena Biopharma Receives Fast Track Designation for NeuVax™ (nelipepimut-S) PRESENT Clinical Trial
June 1 2016 ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread® for Treating Hepatitis B
May 31 2016 ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
May 31 2016 Aytu BioScience to Attend the 2016 Biotechnology Innovation Organization International Convention
May 26 2016 ContraVir Pharmaceuticals to Present at 2016 Marcum MicroCap Conference
May 25 2016 Aytu BioScience to Optimize Capitalization in Support of Future Anticipated Uplisting of its Common Stock to a National Exchange
May 25 2016 ContraVir to Showcase CMX157 Data in Poster at the 3rd ANRS HBV Cure Workshop
May 24 2016

Aytu BioScience to Present at 2016 Marcum MicroCap Conference

May 24 2016 Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum
May 19 2016 Galena Biopharma to Present GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
May 18 2016 Galena Biopharma to Present the GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
May 18 2016 KemPharm, Inc. to Host Annual Meeting of Stockholders on Tuesday, May 24, 2016 at 9:00 a.m. ET
May 18 2016 Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto®
May 12 2016 KemPharm, Inc. Reports First Quarter 2016 Results
May 11 2016 Aytu BioScience Provides Third Fiscal Quarter 2016 Business Update
May 10 2016 Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update
May 10 2016

KemPharm Receives “Fast Track” Designation for KP511, an Investigational Prodrug of Hydromorphone

May 10 2016 Aytu BioScience Demonstrates Expanded Clinical Utility of MiOXSYS™ for Assessing Oxidative Stress as a Marker for Male Infertility with New Study
May 6 2016 Aytu BioScience Announces Closing of Public Offering
May 5 2016 Statement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate Apadaz™
May 5 2016 Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease
May 5 2016 Aytu BioScience to Provide its Third Fiscal Quarter Business Update
May 5 2016 FDA Advisory Committees To Review KemPharm’s Abuse-Deterrent Drug Candidate Apadaz™
May 3 2016 KemPharm, Inc. to Report First Quarter 2016 Results
May 2 2016 Aytu BioScience Announces Pricing of $7.5 Million Public Offering of Common Stock and Warrants
May 2 2016 Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
Apr 21 2016 eNeura, Inc. Receives CE Mark Label Extension Expanding Use of SpringTMS® to Include Migraine Prevention
Apr 21 2016 CorMedix to Present Data from Landmark Post-Approval Surveillance Study at National Kidney Foundation® 2016 Spring Clinical Meetings
Apr 19 2016 Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data at the American Association for Cancer Research (AACR) Annual Meeting
Apr 19 2016 KemPharm Announces New Additions to Senior Leadership Team
Apr 19 2016 Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
Apr 19 2016 ContraVir Doses First Subject in Phase 1b Clinical Study of CMX157 for Treating Chronic Hepatitis B Infection
Apr 18 2016 Aridis Pharmaceuticals Strengthens Board of Directors with Former Wyeth (now Pfizer) President of R&D Robert Ruffolo, Jr.
Apr 15 2016 Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
Apr 14 2016 ContraVir Invited to Present CMX157 Data at Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference
Apr 13 2016 Aytu BioScience Strengthens Board with Appointment of First Independent Director
Apr 12 2016 Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting
Apr 12 2016 CorMedix Inc. to Present Post-Market Clinical Utility Data from Neutrolin Usage Monitoring Program on May 23, 2016
Apr 7 2016 EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE
Apr 5 2016 KemPharm to Present at the Needham & Company’s 15th Annual Healthcare Conference in New York, NY
Apr 5 2016 Aytu BioScience Demonstrates Clinical Utility of MiOXSYS™ for Measuring Oxidative Stress Levels in Semen as a Marker for Male Infertility at American Society of Andrology 41st Annual Meeting in New Orleans, LA
Apr 4 2016 ContraVir Pharmaceuticals, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
Apr 4 2016 ContraVir Invited to Present CMX157 Data at the Oligonucleotide Therapeutics & Delivery Conference
Mar 31 2016 Aytu BioScience Awarded Health Canada Approval for Its MiOXSYS™ System for Male Infertility
Mar 31 2016 Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II
Mar 31 2016 ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer
Mar 30 2016 ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock And Warrants To Purchase Common Stock
Mar 30 2016 CureVac Appoints Leading Experts to its Scientific Advisory Board
Mar 29 2016 ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
Mar 29 2016 Aytu BioScience Announces U.S. Co-Promotion Agreement for Primsol
Mar 29 2016 Galena Biopharma Phase 3 PRESENT Clinical Trial with NeuVax™ (nelipepimut-S) Achieves 70th Qualifying Disease Free Survival Event
Mar 29 2016 ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study
Mar 29 2016 KemPharm Receives Clearance from FDA to Initiate Human Clinical Trials of KP511, an Investigational Prodrug of Hydromorphone
Mar 24 2016 KemPharm Receives NDA User Fee Waiver from FDA
Mar 21 2016 CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion
Mar 21 2016 ContraVir Initiates Phase 1/2a Clinical Study of CMX157 for Treating Chronic Hepatitis B Infection
Mar 17 2016 ContraVir Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell March 21, 2016
Mar 15 2016 Helomics® Launches GeneFx® Colon to Identify Patients with High Risk Stage II Colon Cancer
Mar 14 2016 KemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP
Mar 10 2016 Galena Biopharma Reports Fourth Quarter and Year End 2015 Financial Results and Provides a Corporate Update
Mar 10 2016 KemPharm, Inc. Reports Q4 and Year End 2015 Results
Mar 7 2016
KemPharm Files IND for KP511, an Investigational Prodrug of Hydromorphone
Mar 7 2016
Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results
Mar 7 2016
Galena Biopharma to Present at the 28th Annual ROTH Conference
Mar 3 2016 ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
Mar 3 2016 New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
Mar 2 2016 Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference
Mar 1 2016 Aytu BioScience Announces Study Collaboration with Hybridyne Imaging Technologies for Minimally Invasive Prostate Cancer Detection
Feb 26 2016 Galena Biopharma to Report Fourth Quarter and Year End 2015 Financial Results and Provide a Corporate Update on Thursday, March 10, 2016
Feb 19 2016 KemPharm to Present Data From Oral Human Abuse Liability Study for Investigational Drug KP201/APAP at the 2016 AAPM Annual Meeting
Feb 18 2016 CureVac announces "MERAN" has been approved by the World Health Organization as suffix for mRNA drug substances
Feb 18 2016 XBiotech to Present at 4th Annual Sachs Cancer BioPartnering & Investment Forum
Feb 18 2016 KemPharm, Inc. to Present at Upcoming Investor Conferences
Feb 16 2016 Galena Biopharma Announces Proposed Settlement of Derivative Litigation
Feb 16 2016 Aytu BioScience Provides Second Fiscal Quarter Business Update
Feb 11 2016 Aytu BioScience to Provide its Second Fiscal Quarter Business Update
Feb 11 2016 XBiotech Engages in Research for Heart Attack Antibody Therapy
Feb 10 2016 FDA Grants Priority Review to KemPharm for KP201/APAP NDA
Feb 9 2016 KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
Feb 9 2016 Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS™ System for Male Infertility
Feb 8 2016 Galena Biopharma Announces Notice of Allowance of U.S. Patent for NeuVax™ (nelipepimut-S)
Feb 4 2016 KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
Feb 4 2016 ContraVir Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 3 2016 Aytu BioScience to Present at 2016 Disruptive Growth & Healthcare Conference
Feb 3 2016 EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016
Feb 2 2016 Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016
Feb 2 2016 Galena Biopharma to Present at the BIO CEO & Investor Conference
Jan 29 2016 Helomics® to Present at BIO CEO & Investor Conference
Jan 27 2016 Aytu BioScience Announces Additions to Board of Directors
Jan 27 2016 Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
Jan 25 2016 EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion
Jan 21 2016 CorMedix to Present at National Kidney Foundation® 2016 Spring Clinical Meetings
Jan 21 2016 Galena Biopharma Presents Observational Study Data in Gastric Cancer Patients at the ASCO 2016 Gastrointestinal Cancers Symposium
Jan 19 2016 Enteris BioPharma Enhances Executive Leadership Team to Target Strategic Growth Opportunities
Jan 15 2016 ContraVir Pharmaceuticals to Present at NobleCon12
Jan 13 2016 Galena Biopharma Provides 2016 Outlook
Jan 12 2016 Aytu BioScience Obtains CE Marking for Company's MiOXSYS™ System for Male Infertility
Jan 11 2016 Galena Biopharma to Present at NobleCon12
Jan 8 2016 MDNA Life Sciences Appoints New Management Team Members to Lead Development and Commercialization of Mitochondrial Diagnostic Pipeline
Jan 8 2016 XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix™ in Advanced Colorectal Cancer
Jan 7 2016 Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
Jan 7 2016 KemPharm Added to NASDAQ Biotechnology Index
Jan 7 2016 XBiotech Advances to Final Dosing Cohort in Phase 1/2 Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus
Jan 6 2016 Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
Jan 6 2016 XBiotech Added to NASDAQ Biotechnology Index
Jan 6 2016 CorMedix to Present at Biotech Showcase™ 2016
Jan 6 2016 Aridis Pharmaceuticals to Present at Biotech Showcase™ 2016
Jan 5 2016 MDNA Life Sciences to Present at Biotech Showcase 2016
Jan 5 2015 EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 5 2016

ContraVir Pharmaceuticals to Present at Biotech Showcase 2016

Dec 30 2015 KemPharm, Inc. Expands Pain Therapy Pipeline With Discovery of KP746
Dec 24 2015 Galena Biopharma Announces a Change to Its Board of Directors
Dec 21 2015 CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference
Dec 18 2015 Galena Biopharma to Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture of Commercial Operations
Dec 16 2015 Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures
Dec 15 2015 Aratana Therapeutics to Present at Bank of America Merrill Lynch Animal Health Summit
Dec 15 2015 KemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA
Dec 14 2015 Aytu BioScience Announces Upgrade to OTCQX®
Dec 11 2015 Galena Biopharma Announces Departure of Chief Financial Officer
Dec 9 2015 Celimmune Co-Authors Study Demonstrating Gluten Peptides in Urine Correlate with Mucosal Damage in Celiac Disease
Dec 8 2015

Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 8 2015 ContraVir Reports Key CMX157 Data at HEP DART 2015 Demonstrating Enhanced in vitro Safety Profile Compared to Viread®
Dec 7 2015 Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting
Dec 4 2015 Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits
Dec 3 2015 Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise
Dec 3 2015 KemPharm, Inc. to Present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY
Dec 3 2015 ContraVir Strengthens Board of Directors with Addition of Industry Veteran Arnold Lippa, Ph.D.
Dec 2 2015 Vaccinogen Believes That Its "Whole-Tumor Methodology" and Focus on "Cancer Heterogeneity" is Supported by Research Published in The Proceedings of the National Academy of Sciences (PNAS)
Nov 30 2015 Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference
Nov 20 2015 Aratana Therapeutics to Present at Piper Jaffray Healthcare Conference and Bank of America Merrill Lynch Animal Health Summit
Nov 20 2015 Galena Biopharma Completes Divestiture of Abstral (fentanyl) Sublingual Tablets as Part of Strategic Focus on Its Immunotherapy Pipeline
Nov 20 2015 XBiotech Added to the MSCI US Small Cap 1750 and the MSCI Investable Market 2500 Indexes
Nov 19 2015 Marinus's Ganaxolone to be Featured in Two Poster Presentations at the 69th Annual Meeting of the American Epilepsy Society
Nov 16 2015 Helomics® to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 13 2015 Aratana Therapeutics to Present at Stifel 2015 Healthcare Conference
Nov 12 2015 KemPharm, Inc. Reports Q3 2015 Results
Nov 12 2015 XBiotech Provides Third Quarter 2015 Corporate And Clinical Update
Nov 11 2015 EnGeneIC Ltd. to Present at the Stifel 2015 Healthcare Conference
Nov 11 2015 XBiotech Identifies Positive Donors for Anti-Clostridium difficile Therapeutic Antibody Only Two Weeks After Initial Screening
Nov 10 2015 ContraVir to Present at the Salomon Bio Investment & Leadership Conference
Nov 10 2015 Marinus Pharmaceuticals to Present At Credit Suisse Healthcare Conference
Nov 9 2015 Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business
Nov 9 2015 Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting
Nov 9 2015 XBiotech Announces Positive Results for Its Anti-Ebola Therapeutic Candidates Following Evaluation by USAMRIID
Nov 6 2015 Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 5 2015 KemPharm, Inc. to Report Third Quarter 2015 Results
Nov 5 2015 Marinus Pharmaceuticals Announces Public Offering of Common Stock
Nov 5 2015 XBiotech To Provide Third Quarter Business Update
Nov 4 2015 Vaccinogen Promotes Peter Morsing, Ph.D. to Chief Operating Officer
Nov 3 2015
CureVac Raises $110 Million in a Private Placement
Oct 29 2015 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
Oct 29 2015 Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation
Oct 28 2015 Vaccinogen Engages D. Barry Boyd, M.D., M.S., as Senior Oncology
Oct 26 2015 XBiotech Initiates Program to Develop Antibody Against Clostridium Difficile
Oct 26 2015 Marinus Announces Key Initial Observations From Study in PCDH19 Female Pediatric Epilepsy
Oct 26 2015 Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015
Oct 22 2015 Aytu BioScience Demonstrates Clinical Utility of MiOXSYS® for Measuring Oxidative Stress Levels in Semen as a Marker for Male Infertility
Oct 22 2015 Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences
Oct 21 2015 KemPharm Completes Human Abuse Liability Program For KP201/APAP
Oct 21 2015 Save the Date for Aratana Therapeutics 2015 Investor Day
Oct 21 2015 XBiotech Presents Findings at Investigator Conference for Staphylococcus Aureus Program
Oct 19 2015 XBiotech Strengthens Intellectual Property Portfolio for Its True Human Antibody Technology
Oct 19 2015 Benitec Forms Hepatology Clinical Advisory Board
Oct 16 2015 Aratana Therapeutics Announces a $40 Million Credit Facility
Oct 15 2015 The 3rd International mRNA Health Conference to Celebrate Historic 2015 as "mRNA Grabs the Spotlight"
Oct 15 2015 EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum
Oct 14 2015 Cantex Pharmaceuticals to Present at The 14th Annual BIO Investor Forum
Oct 14 2015 Benitec Biopharma To Present At The 14th Annual BIO Investor Forum
Oct 14 2015 ContraVir To Present At The 14th Annual BIO Investor Forum
Oct 13 2015 Aridis Pharmaceuticals Receives Multiple NIH Grants
Oct 13 2015 KemPharm Enhances U.S. And Global Intellectual Property Estate
Oct 11 2015 Lilly and Innovent Biologics Expand Their Strategic Alliance to Include Immuno-Oncology Bispecific Antibodies in China and Globally
Oct 7 2015 ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock
Oct 7 2015 Lonza and Benitec Enter Agreement to Develop Scalable AAV Manufacturing Process for ddRNAi Therapeutics
Oct 6 2015 ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Oct 6 2015 Aytu BioScience Acquires Second Revenue-Generating Urology Product
Oct 6 2015 Vaccinogen Appoints Michael G. Hagerman to its Board of Directors
Oct 5 2015 ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®
Oct 2 2015 XBiotech Announces Publication of Clinical Results Supporting the Potential of Its True Human Antibody as a Cardiovascular Therapy
Oct 1 2015 XBiotech Receives FDA Fast Track Designation for Its Novel True Human Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus
Sept 30 2015 Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax (nelipepimut-S) in Ductal Carcinoma in Situ Patients
Sept 30 2015 KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
Sept 29 2015
Aytu BioScience Provides First Quarterly Business Update
Sept 28 2015
Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at the European Cancer Congress 2015
Sept 24 2015
Aratana Therapeutics Provides Product Updates
Sept 24 2015 Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
Sept 24 2015 KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone and Immediate Release Oxycodone Prodrug Product Candidates
Sept 24 2015 Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting
Sept 23 2015 Benitec Featured at CHI's "Discovery On Target" Conference
Sept 22 2015 Aytu BioScience To Provide Its First Quarterly Business Update
Sept 16 2015 EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients
Sept 16 2015 Aytu BioScience to Present Study Data at the American Society for Reproductive Medicine's Annual Meeting
Sept 16 2015 Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial
Sept 10 2015

IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

Sept 10 2015 CureVac Establishes U.S. Operations in Cambridge, MA
Sept 9 2015 Vaccinogen Enhances Patient-Derived Antibody Program with Revolutionary High-Throughput Single Cell Screening and Analysis System
Sept 9 2015 Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures
Sept 9 2015 Aytu BioScience Appoints Jonathan Heath McGrael as Vice President of Sales
Sept 8 2015 KemPharm Data to be Presented at PAINWeek 2015
Sept 2 2015 Aytu BioScience Completes $5.175 Million Private Placement
Sept 2 2015 ContraVir Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference
Sept 1 2015 Galena Biopharma to Present at Two Upcoming Healthcare Investment Conferences
Sept 1 2015 XBiotech Advances Phase 1/2 Clinical Study of Novel True Human Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus
Aug 24 2015 Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ
Aug 24 2015 Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax PRESENT Trial
Aug 18 2015 Benitec Announces Pricing Of An Initial Public Offering In The United States With Listing On NASDAQ
Aug 17 2015 BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment
Aug 17 2015 XBiotech Completes Enrollment for Xilonix Phase III Registration Study in Europe
Aug 13 2015 KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results
Aug 13 2015 Cantex Pharmaceuticals Enhances Executive Management Team
Aug 13 2015 KemPharm, Inc. to Report Pharmacokinetic Data From Intranasal Human Abuse Liability Study on Second Quarter Conference Call
Aug 13 2015 Aytu BioScience Announces Effectiveness of Resale Registration of Common Shares for Certain Existing Security Holders
Aug 13 2015 BioLineRx to Report Second Quarter 2015 Results on August 20, 2015
Aug 10 2015 Helomics Named Tech 50 Finalist by Pittsburgh Technology Council
Aug 10 2015 Aratana Therapeutics Elects Wendy Yarno as Chairman of the Board of Directors
Aug 7 2015 XBiotech Announces Expansion of Global Phase 3 Registration Study in Europe using Xilonix(TM) for Treatment of Metastatic Colorectal Cancer
Aug 6 2015 KemPharm, Inc. to Report Q2 2015 Results
Aug 6 2015 Aratana Therapeutics Reports Second Quarter 2015 Results
Aug 6 2015 Galena Biopharma Reports Second Quarter 2015 Financial Results
Aug 4 2015 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2015 Financial Results
Aug 4 2015 KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conference
Aug 4 2015 Collaboration to Develop mRNA Vaccines Expands
Aug 4 2015 ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com
Aug 3 2015 ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
July 30 2015 Aratana Therapeutics Announces Positive Pilot Field Study for AT-016
July 29 2015 Galena Biopharma Launches Zuplenz® (ondansetron) Oral Soluble Film
July 28 2015 XBiotech Provides Second Quarter 2015 Corporate and Clinical Update
July 27 2015 Aratana Therapeutics Announces Positive Pilot Field Study of AT-002 in Cats
July 27 2015 BioLineRx Announces Top-Line Results from Bellerophon's PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BL-1040)
July 22 2015 Aratana Therapeutics Provides Update on Monoclonal Antibody Products
July 21 2015 Aratana Therapeutics to Report Second Quarter Results
July 15 2015 XBiotech to Provide Second Quarter Business Update
July 14 2015 Aratana Therapeutics Announces Positive Pivotal Results for AT-003
July 14 2015 Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer
July 9 2015 Monopar Therapeutics Announces Partnership With Cancer Research UK And Cancer Research Technology To Develop New Oncology Compound
July 9 2015 Benitec Acquires Full Rights To Hepatitis B Program
July 8 2015 Aridis Pharmaceuticals Expands Phase 2a Trial Into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia
July 7 2015 Aytu BioScience Announces Stock Ticker Symbol Change
July 7 2015 Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council 's Education U.K. Alumni Award
July 7 2015 XBiotech Announces Publication of Clinical Results Supporting Its True Human Antibody Therapy for Type 2 Diabetes Mellitus
July 7 2015 CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer
July 6 2015 XBiotech Treats First Patient in Phase 1/2 Clinical Study of Novel True Human Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus
July 6 2015 Published Data Support Scientific Basis for Ganaxolone Use in PCDH19 Female Epilepsy
July 1 2015 ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference
July 1 2015 XBiotech Conducts Investigators Meeting to Update the Status of Its Phase III Registration Study Underway in Europe
June 30 2015 Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
June 26 2015 Aratana Therapeutics Announces Positive Pivotal Results for AT-002
June 25 2015 KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities
June 24 2015 CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs
June 24 2015 XBiotech Added to Russell 2000 Index
June 23 2015 EnGeneIC Recognized as One of the Most Innovative Organizations in Australia at the 2015 Thomson Reuters Australian Citation & Innovation Awards
June 22 2015 Benitec Enters into Strategic Collaboration with ReNeuron to Develop Cellular Therapies
June 22 2015 Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714 at 16th International Coeliac Disease Symposium
June 17 2015 BioLineRx to Present Successful Results of Phase 1/2 Study for Novel Celiac Treatment at International Celiac Disease Symposium
June 16 2015 Marinus Pharmaceuticals to Present at JMP Securities Life Sciences Conference
June 16 2015 BioLineRx to Present at the JMP Securities Life Sciences Conference in New York
June 15 2015 ContraVir CEO James Sapirstein Appointed to BIO's ECS Board of Directors and BioNJ's Board of Trustees
June 15 2015 EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma Patients
June 15 2015 XBiotech Announces Publication of Phase 2 Clinical Results for Its True Human Antibody MABp1 for Treating Acne Vulgaris
June 15 2015 Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress
June 15 2015 BioLineRx Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference
June 11 2015 KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP
June 9 2015 Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic
June 8 2015 XBiotech Appoints Kelly R. Thornburg as Senior Vice President of Operations
June 8 2015 ContraVir to Present at BIO International Convention
June 3 2015 ContraVir Engages the Baruch S. Blumberg Institute to Further Research and Develop CMX157
June 3 2015 Research Underlying BioLineRx's Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award
June 3 2015 InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline ; Initiates Discovery and Preclinical Work with Novel Cannabinoid-based Therapy
June 2 2015 Aratana Therapeutics to Participate in Two Upcoming Investor Conferences
June 2 2015 Rosewind Corporation to Become Aytu BioScience, Inc.
June 1 2015 Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
June 1 2015 BioLineRx Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions
May 28 2015 XBiotech Launching Phase 1/2 Clinical Study of Novel True Human Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus
May 27 2015 KemPharm, Inc. Reports Q1 2015 Results
May 27 2015 Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting
May 27 2015 BioLineRx to Present Positive Safety and Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at the European Hematology Annual Congress
May 26 2015 XBiotech Successfully Clones First Anti-Ebola Therapeutic Antibody Product Candidate
May 26 2015 InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)
May 22 2015 Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress
May 21 2015 KemPharm Completes Pre-NDA Meeting With FDA for KP201/APAP
May 21 2015 Advaxis Appoints Fred J. Frullo Vice President, Regulatory Affairs
May 19 2015 KemPharm's KP201/APAP Featured at the 2015 Abuse Deterrent Formulations Summit
May 19 2015 Advaxis and Sorrento Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies
May 18 2015 KemPharm, Inc. to Report Q1 2015 Results
May 18 2015 Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
May 18 2015 XBiotech Secures Approval From Data Safety Monitoring Board to Continue Phase 3 Registration Study in Europe for Its Novel Cancer Immunotherapy
May 18 2015 Rosewind Corporation to Present at 2015 Marcum MicroCap Conference
May 18 2015 Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference
May 18 2015 BioLineRx Reports First Quarter 2015 Financial Results
May 15 2015 Aratana Therapeutics to Participate in Two Upcoming Investor Conferences
May 14 2015 Aratana Therapeutics to Showcase Extensive Clinical Development Pipeline at ACVIM
May 12 2015 InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
May 12 2015 ContraVir to Present at Cavendish Global Health Impact Forum
May 11 2015 Helomics CEO Named to Pennsylvania Bio Board of Directors
May 11 2015 Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2015 Financial Results
May 11 2015 BioLineRx to Report First Quarter 2015 Results on May 18, 2015
May 7 2015 Aratana Therapeutics Reports First Quarter 2015 Results
May 7 2015 Galena Biopharma Reports First Quarter 2015 Financial Results
May 6 2015 Advaxis Appoints Thomas W. Hare Vice President, Clinical Operations
May 5 2015 CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015
May 5 2015 Advaxis Announces Closing Public Offering of Common Stock With Gross Proceeds Totaling $53.2 Million
May 5 2015 InMed Engages Peter Mountford as Strategic Advisor
May 4 2015 Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets
May 4 2015 BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia
May 1 2015 Aratana Therapeutics Inc. to Report first Quarter Results
Apr 30 2015 InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.
Apr 30 2015 Advaxis Prices $53 Million Public Offering of Common Stock
Apr 29 2015 Advaxis Announces Proposed Public Offering of Common Stock
Apr 29 2015 XBiotech Enrolls First Patient Under Revised Protocol for U.S. Phase 3 Registration Study Using Xilonix for Treatment of Metastatic Colorectal Cancer
Apr 29 2015 Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
Apr 28 2015 Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property Portfolio With Two USPTO Patents Addressing ADXS-PSA and ADXS-HER2
Apr 27 2015 Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015
Apr 23 2015 Galena Biopharma to Report First Quarter Financial Results on Thursday, May 7, 2015
Apr 22 2015 Aratana Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Apr 21 2015 Advaxis Presents Lm-LLO Cancer Immunotherapy Data at the 2015 American Association for Cancer Research Meeting
Apr 16 2015 XBiotech Closes Initial Public Offering
Apr 16 2015 Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions
Apr 15 2015 KemPharm Announces Pricing of Initial Public Offering
Apr 14 2015 XBiotech Announces Pricing of Initial Public Offering
Apr 14 2015 Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
Apr 10 2015 Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
Apr 10 2015 Advaxis Included Among "25 Top Immunotherapy Companies" in Newly Launched Loncar Cancer Immunotherapy Index (LCINDX)
Apr 9 2015 Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, to Board of Directors
Apr 9 2015 Helomics to Present at the Personalized Medicine World Conference in Oxford, England
Apr 8 2015 Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
Apr 7 2015 Benitec Provides Update On TT-034 Trial
Apr 6 2015 Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer
Apr 1 2015 XBiotech Announces Publication of Positive Clinical Results for Xilonix in Non-Small Cell Lung Cancer
Mar 31 2015 InMed Pharmaceuticals Strengthens Scientific Advisory Board
Mar 31 2015 Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference
Mar 31 2015 Orthofix International Secures Option to Acquire eNeura, Inc.
Mar 26 2015 Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin Monoclonal Antibody for Acute Pneumonia
Mar 26 2015 Advaxis to Present at the Jefferies Immuno-Oncology Summit
Mar 26 2015 Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients
Mar 26 2015 Helomics Partners with Leading Global Healthcare Companies to Support The 100,000 Genomes Project
Mar 25 2015 Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy
Mar 25 2015 BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment
Mar 23 2015 Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., as Chief Medical Officer
Mar 23 2015 BioLineRx Reports Year End 2014 Financial Results
Mar 20 2015 Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
Mar 19 2015 Aratana Therapeutics to Present at the Jefferies 2015 Animal Health Summit
Mar 19 2015 Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer
Mar 18 2015 Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
Mar 18 2015 Advaxis's Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations at the 2015 American Association for Cancer Research Annual Meeting
Mar 18 2015 Helomics Launches Precision Cellular Analytical Platform (PCAP) Expanding their Comprehensive Tumor Profiling Offering to Patients, Physicians and Life Science Industry
Mar 18 2015 Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension
Mar 17 2015 BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015
Mar 16 2015 Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients
Mar 16 2015 Marinus Pharmaceuticals to Participate in Future Leaders in the Biotech Industry Conference
Mar 12 2015

Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants

Mar 12 2015 Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results
Mar 12 2015 Helomics to Present at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York
Mar 11 2015 BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
Mar 11 2015 Helomics, Prime Health Services Sign Contract to Expand Access to ChemoFx(R) And Comprehensive Tumor Profiling
Mar 11 2015 Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial
Mar 11 2015 Aratana Therapeutics Inc. to Report Fourth Quarter and Year-End Financial Results
Mar 11 2015 Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial
Mar 11 2015 BioLineRx 's Treatment for Type 1 Diabetes Effective in Preclinical Trials
Mar 10 2015 InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies
Mar 10 2015 KemPharm, Inc. Appoints David S. Tierney, MD to Board of Directors
Mar 9 2015 ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
Mar 6 2015 BioLineRx to Present at the Annual Roth Conference in California
Mar 6 2015 BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary Shares
Mar 5 2015 BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
Mar 5 2015 Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results
Mar 5 2015 Advaxis to Present at the 27th Annual ROTH Conference
Mar 5 2015 ContraVir to Present at 27th Annual ROTH Conference
Mar 4 2015 Aratana Therapeutics to Present at the Barclays Global Healthcare Conference
Mar 4 2015 KemPharm, Inc. Appoints Tracy M. Woody as Chief Commercial Officer
Mar 4 2015 InMed Pharmaceuticals Appoints Dr. Ado Mohammed as Chief Medical Officer
Mar 3 2015 Galena Biopharma to Present at the 27th Annual ROTH Conference
Mar 2 2015 InMed Pharmaceuticals to Present Investor Webcast March 5
Mar 2 2015 Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
Mar 2 2015 Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen
Mar 2 2015 BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment
Feb 26 2015 Advaxis to Present at International Anal Neoplasia Society Scientific Meeting 2015
Feb 25 2015 ContraVir Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
Feb 24 2015 Aratana Therapeutics Regains Rights to AT-004
Feb 24 2015 Marinus Pharmaceuticals to Participate in Cowen & Company Annual Healthcare Conference
Feb 23 2015 Celimmune Founded to Develop Novel Therapeutics for Celiac and Other Serious Autoimmune Diseases
Feb 20 2015 ContraVir Pharmaceuticals Provides Clinical Update on FV-100
Feb 19 2015 Galena Biopharma to Report Fourth Quarter and Year End 2014 Financial Results on Thursday, March 5, 2015
Feb 18 2015 Advaxis Completes $23 Million Financing
Feb 13 2015 Advaxis Appoints Mayo Pujols Vice President, Manufacturing
Feb 11 2015 Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
Feb 10 2015 Aratana Therapeutics Provides Product Updates
Feb 10 2015 Enteris BioPharma Launches Contract Manufacturing within 32,000 Square Foot, FDA inspected and cGMP Compliant Facility
Feb 9 2015 Marinus Pharmaceuticals to Participate in Leerink Global Healthcare Conference
Feb 9 2015 Galena Biopharma Enrolls 700th Patient in NeuVax (nelipepimut-S) Phase 3 PRESENT Clinical Trial
Feb 6 2015 Aratana Therapeutics to Present at the Leerink Global Healthcare Conference
Feb 5 2015 Galena Biopharma Announces Orexo's Filing of a Patent Infringement Lawsuit Against Actavis Concerning Abstral(R) (fentanyl) Sublingual Tablets in the U.S.
Feb 4 2015 EnGeneIC to Present at BIO CEO & Investor Conference 2015
Feb 4 2015 ContraVir Pharmaceuticals ' HBV Compound CMX157 Receives Extended Patent Life
Feb 3 2015 Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy
Feb 3 2015 BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10
Feb 3 2015 InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS)
Feb 2 2015 Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 2 2015 ContraVir to Present at Two Upcoming Investor Conferences
Jan 28 2015 AnaMar Announces Strategic Realignment and 2015 Corporate Priorities
Jan 28 2015 Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria
Jan 28 2015 Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
Jan 27 2015 Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
Jan 21 2015 Helomics to Present at the Personalized Medicine World Conference
Jan 20 2015 Advaxis to Host Analyst & Investor Day on February 3, 2015
Jan 20 2015 Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management
Jan 20 2015 ContraVir Pharmaceuticals Adds Carol L. Brosgart, M.D., to Scientific Advisory Board
Jan 19 2015 Aratana Therapeutics Awarded "Best Pipeline 2014" by Animal Pharm
Jan 7 2015 Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer
Jan 7 2015 Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer
Jan 7 2015 Relburn-Metabolomics to Present at Biotech Showcase 2015
Jan 7 2015 ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
Jan 6 2015 Helomics to Present at Biotech Showcase 2015 During the JP Morgan Healthcare Conference
Jan 6 2015 EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor
Jan 6 2015 BioLineRx Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization Treatment
Jan 6 2015 Luoxis to Present at Biotech Showcase 2015
Jan 6 2015 BioLineRx to Present at Biotech Showcase 2015 Conference in San Francisco
Jan 6 2015 ContraVir Pharmaceuticals to Present at Biotech Showcase 2015
Jan 5 2015 Aratana Therapeutics Granted Full License for AT-004 by USDA
Jan 5 2015 Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2
Dec 30 2014 Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall
Dec 23 2014 BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma
Dec 19 2014 Advaxis Completes $17 Million Financing
Dec 18 2014 Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis
Dec 18 2014 Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
Dec 16 2014 Aratana Therapeutics Initiates Pivotal Study for AT-003
Dec 16 2014 BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates
Dec 16 2014 ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
Dec 15 2014 Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers
Dec 12 2014 BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform
Dec 12 2014 Advaxis's Cancer Immunotherapies Featured on FOX News
Dec 11 2014 ContraVir Pharmaceuticals' CEO Issues Letter to Shareholders Highlighting Significant Progress
Dec 11 2014 Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle Results From the Phase 3 NeuVax (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
Dec 11 2014 Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology
Dec 9 2014 Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial
Dec 9 2014 KemPharm, Inc. Completes Pre-IND Meeting with FDA for NME Prodrug of Hydromorphone, KP511
Dec 9 2014 ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
Dec 8 2014 Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer
Dec 8 2014 Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
Dec 8 2014 BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference
Dec 5 2014 Aratana Therapeutics to Present at the 2014 Animal & Dental Health Summit
Dec 5 2014 KemPharm, Inc. Receives Notice of Allowance for NME Prodrug of Methylphenidate, KP415
Dec 5 2014 Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
Dec 2 2014 Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter
Dec 1 2014 Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
Nov 28 2014 Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Nov 26 2014 Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board
Nov 25 2014 Advaxis to Present at the LD Micro Conference
Nov 25 2014 Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference
Nov 24 2014

Medac Pharma, Inc. Brings Motion to Preliminarily Prohibit Antares Sales of Otrexup to New Patients

Nov 20 2014 Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress
Nov 20 2014 Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
Nov 18 2014 Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Nov 18 2014 Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Nov 18 2014 Helomics to Be Recognized at the 2014 Pittsburgh Smart 50 Awards
Nov 17 2014 Aratana Therapeutics to Present at Jefferies Global Healthcare Conference
Nov 13 2014 Galena Biopharma to Present at the Stifel 2014 Healthcare Conference
Nov 12 2014 Precision Therapeutics Transforms into Helomics™ Corporation
Nov 12 2014 Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune 's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer
Nov 10 2014 EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma
Nov 10 2014 BioLineRx Reports Third Quarter 2014 Financial Results
Nov 5 2014 Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nov 5 2014 ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum
Nov 5 2014 BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment
Nov 4 2014 Aratana Therapeutics Inc. to Report Third Quarter Financial Results
Nov 4 2014 Advaxis to Present Survival Data of Lm-LLO Cancer Immunotherapies in Recurrent Cervical Cancer and Canine Osteosarcoma at the Society for Immunotherapy of Cancer 29th Annual Meeting
Nov 4 2014 Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014
Nov 4 2014 Galena Biopharma Reports Third Quarter 2014 Results
Nov 3 2014 BioLineRx to Report Third Quarter 2014 Results on November 10, 2014
Nov 3 2014 BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile
Oct 31 2014 BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
Oct 30 2014 AnaMar AB Reports Top-Line Results from Exploratory Phase 2a Study of AMAP102 and Provides Corporate Update
Oct 30 2014 Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study
Oct 27 2014 Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014
Oct 22 2014 MedHab, LLC. Establishes Partnership With Olympic Champion Michael D. Johnson and Michael Johnson Performance, Inc.
Oct 22 2014 Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program
Oct 20 2014 Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences
Oct 16 2014 ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
Oct 15 2014 Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board
Oct 15 2014 ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
Oct 14 2014 Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax (nelipepimut-S) in Japan
Oct 13 2014 Aratana Therapeutics and Atopix Complete Global Licensing Agreement for Development and Commercialization of Novel Atopic Dermatitis Program
Oct 10 2014 Aratana Therapeutics Announces Presentation of Clinical Data at Annual Veterinary Cancer Society Meeting
Oct 8 2014 Advaxis Appoints World Renowned Oncologist and Research Scientist, Dr. Samir N. Khleif, to Its Board of Directors
Oct 6 2014 Medac Pharma, Inc.'s Rasuvo (methotrexate) injection Now Available for Patients With Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
Oct 6 2014 Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate
Oct 1 2014 Advaxis's Chief Scientific Officer, Dr. Robert Petit, Leads Panel Discussion on Combination Immunotherapies
Oct 1 2014 Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.
Sept 30 2014 KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511
Sept 26 2014 Advaxis's Cancer Immunotherapy Featured on Fox News
Sept 25 2014 Galena Biopharma Announces Release of Special Committee Report and Hosting of a Conference Call to Provide a Corporate Update
Sept 23 2014 KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada
Sept 18 2014 Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Sept 18 2014 Technical Vision Inc. Launches My Mobile Light Low Vision Mobility Aid
Sept 17 2014 Aratana Therapeutics, Inc. Announces Pricing of Public Offering
Sept 17 2014 BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations
Sept 16 2014 Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day
Sept 16 2014 Omni Bio to Present at 7th Annual BioPharm America Conference
Sept 15 2014 EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research
Sept 12 2014 Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
Sept 11 2014 Synthetic Biologics to Host Phase II Trimesta for Multiple Sclerosis Conference Call
Sept 10 2014 Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day
Sept 9 2014 Aratana Therapeutics Reports Positive Effectiveness Data from Pilot Field Study of Bupivacaine Extended-Release Injectable Suspension (AT-003)
Sept 9 2014 Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Sept 9 2014 Advaxis Provides a Clinical Development Update for Its Immunotherapy, ADXS-HPV, for the Treatment of Cervical Cancer
Sept 8 2014 KemPharm, Inc. Advances KP201 Clinical Program with Initiation of Human Abuse Liability and Human Gastrointestinal Motility Trials
Sept 8 2014 Advaxis to Present at Upcoming Investor Conferences
Sept 8 2014 Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
Sept 7 2014 Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
Sept 5 2014 Aratana Therapeutics to Present at Morgan Stanley Global Healthcare Conference
Sept 5 2014 ContraVir to Present at Two Upcoming Investor Conferences
Sept 5 2014 Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
Sept 5 2014 BioLineRx Doses First Patient for BL-8040's Second Indication as Novel Stem Cell Mobilization Treatment
Sept 3 2014 Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
Sept 2 2014 Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
Sept 2 2014 BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 26 2014 Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile
Aug 26 2014 Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014
Aug 25 2014 Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
Aug 21 2014 Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Aug 21 2014 BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten Toxicity
Aug 19 2014 Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
Aug 19 2014 Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
Aug 19 2014 Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
Aug 13 2014 Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day
Aug 12 2014 Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
Aug 12 2014 Aratana Therapeutics Reports Second Quarter 2014 Results
Aug 11 2014 Galena Biopharma Reports Second Quarter 2014 Results
Aug 11 2014 EnGeneIC Receives Patent from the USPTO for EDV™ Nanocell Technology
Aug 11 2014 Advaxis's Scientific Founder, Dr. Yvonne Paterson, Named One of the PharmaVOICE 100 Most Inspiring People in Life Sciences
Aug 11 2014 Venaxis Announces Regulatory and Market Development Progress
Aug 11 2014 Luoxis Broadens Global Research Network for RedoxSYS™ ORP (oxidation-reduction potential) diagnostic system
Aug 7 2014 Aratana Therapeutics Appoints Irvine Hockaday to Board of Directors
Aug 7 2014 Synthetic Biologics to Report Second Quarter 2014 Financial Results
Aug 6 2014 KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Aug 6 2014 BioLineRx Reports Second Quarter 2014 Financial Results
Aug 6 2014 Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
Aug 5 2014 Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors
July 31 2014 Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
July 30 2014 BioLineRx to Report Second Quarter 2014 Results on August 6, 2014
July 29 2014 Advaxis and the University of Pennsylvania Restructure Their Exclusive License Agreement
July 29 2014 Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014
July 28 2014 Advaxis Receives Notice of Allowance for Cancer Immunotherapies Patent in Japan
July 22 2014 Galena Biopharma Enters Into Definitive Agreement to License U.S. Rights for Zuplenz (ondansetron) Oral Soluble Film
July 22 2014 Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial
July 21 2014 Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
July 16 2014 Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
July 16 2014 BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment
July 14 2014 Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
July 2 2014 Advaxis Announces Filing for USDA Product License
July 2 2014 Aratana Therapeutics Files for USDA Product License of AT-014 Canine Osteosarcoma Immunotherapy
July 1 2014 Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax(TM) (nelipepimut-S)
June 30 2014 Oligomerix, Inc. to Present its Drug Discovery Program Targeting Tau Oligomers at the Federation of European Neuroscience Societies Forum and the Alzheimer's Association International Conference
June 30 2014 Advaxis's Cancer Immunotherapy Featured on CBS News
June 30 2014 Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program
June 25, 2014 Advaxis to be Added to Russell Microcap Index
June 25, 2014 Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves Insulin Sensitivity and Lipid Profiles in Study of Pre-Diabetic, Obese Patients
June 24, 2014 EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology
June 23, 2014 Aratana Therapeutics Adds Robert P. Roche, Jr. to Board of Directors
June 23, 2014 Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
June 23, 2014 Advaxis Receives Notice of Allowance From U.S. Patent Office for Two Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy ADXS-cHER2
June 23, 2014 BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain
June 20, 2014 Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug
June 18, 2014 Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-cell Lymphoma
June 18, 2014 Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society : ICE/ENDO 2014
June 16, 2014 Advaxis Evaluates Higher Dose and Repeat Cycles of ADXS-HPV in Phase 1/2 Cervical Cancer Trial
June 16, 2014 Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
June 13, 2014 Aratana Therapeutics Expands Pain Franchise with Novel Regenerative Cell Therapy for Treating Osteoarthritis
June 12, 2014 Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
June 12, 2014 Advaxis to Present at BIO International Convention
June 11, 2014 BioLineRx Receives Notice of Allowance for US Patent Covering Novel Treatment for Celiac Disease
June 10, 2014 Advaxis Provides Business Update
June 10, 2014 Synthetic Biologics and Enterome Bioscience Collaborate on Microbiome Research to Support Synthetic Biologics' C. difficile Program
June 9, 2014 Aratana Therapeutics Presents Safety and Clinical Findings at 2014 ACVIM Forum
June 6, 2014 Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in Canine Osteosarcoma
June 4, 2014 Data Published by Researchers at the National Cancer Institute Further Identifies How Advaxis's Lm-LLO Immunotherapy Eradicates Tumors
June 3, 2014 KemPharm, Inc. Secures $60 Million Commitment from Deerfield
May 31, 2014 Advaxis Presents New Long-Term Survival Data Greater Than 24-Months at ASCO Annual Meeting
May 30, 2014 BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital
May 30, 2014 Aratana Therapeutics to Participate in Upcoming Investor Conferences
May 29, 2014 Advaxis Selects inVentiv Health Clinical to Conduct Clinical Trials of Immunotherapy Candidates
May 29, 2014 Islet Sciences, Inc. Appoints Steven Delmar as Chief Financial Officer
May 29, 2014 Advaxis Selects inVentiv Health Clinical to Conduct Clinical Trials of Immunotherapy Candidates
May 27, 2014 Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma
May 23, 2014 eNeura Inc. Receives FDA Clearance for SpringTMS Migraine Treatment Device
May 23, 2014 Aratana Therapeutics to Participate in Two Upcoming Investor Conferences
May 20, 2014 Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor Conference
May 20, 2014 Synthetic Biologics to Present at the 3rd Annual Marcum LLP MicroCap Conference
May 20, 2014 BioLineRx Reports First Quarter 2014 Financial Results
May 15, 2014 BioLineRx to Report First Quarter 2014 Results on May 20, 2014
May 15, 2014 Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights
May 14, 2014 Medac Pharma, Inc. Announces Successful FDA Inspection Of Its Exclusive Methotrexate Manufacturer
May 13, 2014 Aratana Therapeutics Reports First Quarter 2014 Results
May 13, 2014 MedHab, LLC. to Present on Smart Insole Tracking System at the 7th International PETRA Conference
May 13, 2014 Advaxis Principal Investigator to Present ADXS-cHER2 Data in Canine Osteosarcoma at American College of Veterinary Internal Medicine Forum
May 12, 2014 Aratana Therapeutics Initiates Pivotal Study for AT-001
May 9, 2014 Synthetic Biologics to Report First Quarter 2014 Financial Results
May 8, 2014 Synthetic Biologics Announces Recent International Patents that Bolster its C. difficile Program
May 5, 2014 Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
May 5, 2014 Aratana Therapeutics Inc. to Report First Quarter Financial Results
May 2, 2014 Aratana Therapeutics to Present at 2014 ACVIM Forum
May 1, 2014 Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer
Apr 30, 2014 KemPharm, Inc. Receives Notice of Allowance for Novel Prodrug of Hydromorphone
Apr 30, 2014 Synthetic Biologics to Discuss Phase II Results of Oral Estriol Candidate Trimesta™ for Relapsing-Remitting Multiple Sclerosis in Women
Apr 29, 2014 Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Apr 24 2014 Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
Apr 23 2014 Synthetic Biologics Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic
Apr 22 2014 Luoxis Awarded Health Canada Approval for RedoxSYS Diagnostic System
Apr 15 2014 Medac Pharma, Inc. Secures FDA Approval of Trade Name Rasuvo™ for Lead Methotrexate Subcutaneous Injectable Product
Apr 14 2014 Benitec Biopharma Completes AUD $31.5 million Private Placement
Apr 14 2014 Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
Apr 14 2014 Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board
Apr 10 2014 BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
Apr 8 2014 Venaxis, Inc. Closes Public Offering of Common Shares
Apr 3 2014 Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares
Apr 2 2014 Luoxis Obtains CE Marking for RedoxSYS™ Diagnostic System
Apr 1 2014 Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications
Mar 31, 2014 Advaxis Announces Closing of Public Offering of Common Stock
Mar 31, 2014 Venaxis Files for FDA Clearance of APPY1 Test
Mar 31, 2014 Prana Biotechnology announces preliminary results of Phase 2 IMAGINE trial of PBT2 in Alzheimer's disease
Mar 28, 2014 Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
Mar 27, 2014 Aratana Therapeutics Adds David Brinkley to Board of Directors
Mar 26, 2014 Advaxis Announces Pricing of Public Offering of Common Stock
Mar 26, 2014 Advaxis to Ring The NASDAQ Stock Market Closing Bell
Mar 24, 2014 Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
Mar 21, 2014 ATL1103 Acromegaly Phase II Trial Recruitment Completed
Mar 19, 2014 Aratana and Advaxis Enter Exclusive Global Licensing Agreement
Mar 18, 2014 Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer
Mar 17, 2014 BioLineRx Reports Year End 2013 Financial Results
Mar 17, 2014 Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
Mar 14, 2014 BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy
Mar 13, 2014 Advaxis to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Mar 13, 2014 Aratana Therapeutics Reports Fourth Quarter and Full Year 2013 Results
Mar 13, 2014 Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test
Mar 12, 2014 Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
Mar 11, 2014 Aratana Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results
Mar 11, 2014 BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
Mar 10, 2014 BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Mar 5 2014 BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
Mar 4 2014 BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Mar 4 2014 KemPharm, Inc. Expands Global Intellectual Property Estate for KP201
Mar 3 2014 BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
Mar 3 2014 Advaxis Cancer Immunotherapy Featured on CNN
Feb 26, 2014 KemPharm, Inc. to Present at Cowen and Company 34th Annual Health Care Conference
Feb 24, 2014 Benitec Biopharma Announces Private Placement of Ordinary Shares and Warrants
Feb 24, 2014 BioLineRx Appoints Dr. Sandra Panem to Board of Directors
Feb 18, 2014 Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day
Feb 18, 2014 Prana Meets Primary Endpoint in Phase 2 REACH2HD Clinical Study of PBT2 for Treating Huntington Disease
Feb 12, 2014 Advaxis to Present at the Bloomberg 2014 State of Healthcare Summit
Feb 12, 2014

BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

Feb 11, 2014 Advaxis Engages SynCo Bio Partners for Manufacturing of ADXS-HPV, Its Lead Cancer Immunotherapy Program
Feb 5, 2014 Aratana Therapeutics Announces Additions to Board of Directors
Feb 5, 2014 KemPharm, Inc. to Present at 16th Annual BIO CEO & Investor Conference
Feb 5, 2014 Advaxis Expands Collaboration With GRU Cancer Center at Georgia Regents University to Conduct Four Cancer Immunotherapy Clinical Trials
Feb 3, 2014 BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10th
Jan 30 2014 Agfa HealthCare targets greater efficiencies and collaboration in Enterprise Imaging during HIMSS 2014 as ICIS becomes the “Gold Standard” for the evolution of visual healthcare
Jan 29 2014 Aratana Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 29 2014 Aratana Therapeutics, Inc . Announces Upsizing and Pricing of Public Offering
Jan 28 2014 Aratana Therapeutics Announces Conditional Approval of Second Canine-Specific Antibody Therapy
Jan 27 2014 Medac Pharma, Inc. Secures FDA Acceptance of a New Drug Application (NDA) for Methotrexate-Containing Autopen
Jan 27 2014 eNeura Files 510(k) with the FDA for SpringTMS® Migraine Treatment
Jan 24 2014 Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1™ Test
Jan 23 2014 BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment
Jan 22 2014 Aratana Therapeutics, Inc. Announces Proposed Public Offering
Jan 22 2014 eNeura's SpringTMS® Migraine Treatment Receives Positive NICE Guidance
Jan 22 2014 Prana commences US Investor Roadshow
Jan 21 2014 Promentis Pharmaceuticals Raises Nearly $3 Million in Series B Financing
Jan 21 2014 BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment
Jan 14 2014 ANTISENSE THERAPEUTICS LIMITED; ANP Presentation at Biotech Showcase 2014
Jan 14 2014 Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College
Jan 13 2014 KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
Jan 13 2014 BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment
Jan 9 2014 KemPharm, Inc. to Present at Biotech Showcase™ 2014
Jan 9 2014 Enteris BioPharma to Present at Biotech Showcase™ 2014
Jan 9 2014 Venaxis to Present at Biotech Showcase™ 2014
Jan 8 2014 Target Enrollment Achieved in CAVATAK™ USA Phase 2 Melanoma Trial with Excellent Interim Results
Jan 8 2014 BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment
Jan 7 2014 Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014
Jan 7 2014 Oligomerix to Present at Biotech Showcase™ 2014
Jan 7 2014 BioLineRx to Present at Biotech Showcase Conference in San Francisco
Dec 23 2013 Aratana Therapeutics Provides 2013 Development Update
Dec 23 2013 Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial
Dec 18 2013 BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
Dec 18 2013 Biotech Showcase™ program speakers have their fingers on the pulse of biotech
Dec 17 2013 Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
Dec 16 2013 BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Dec 11 2013 Aratana Therapeutics to Participate in Upcoming Investor Events
Dec 9 2013 Regado Biosciences Strengthens Executive Leadership
Dec 6 2013 Regado Biosciences, Inc. to Present at Oppenheimer's 24th Annual Healthcare Conference
Dec 4 2013 KemPharm, Inc. to Present at Oppenheimer 24th Annual Healthcare Conference in New York City
Dec 3 2013 Enteris BioPharma Forms Scientific Advisory Board to Enhance Leadership in Oral Delivery of Peptide and Small Molecule Drugs
Dec 3 2013 Experienced Drug Development and Partnering CEO Takes the Helm at Tolera
Nov 21 2013 Sixth Annual Biotech Showcase™ returns to San Francisco January 13–15
Nov 21 2013 Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Nov 20 2013 Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Nov 19 2013 Aratana Therapeutics to Present at Two Upcoming Investor Conferences
Nov 18 2013 Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
Nov 13 2013 Aratana Therapeutics Reports Third Quarter 2013 Financial Results
Nov 11 2013 Accera, Inc. to Moderate Symposium on Metabolic Dysregulation in Alzheimer's Disease During the 6th Annual Clinical Trials Conference on Alzheimer's Disease (CTAD)
Nov 11 2013 Aratana Therapeutics Strengthens Executive Management Team to Support Growth and Commercialization Initiatives
Nov 7 2013 Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 7 2013 Regado Biosciences, Inc. Announces Third Quarter 2013 Results
Nov 7 2013 Venaxis Nears Completion of Pivotal Clinical Trial of APPY1™ Test
Nov 5 2013 Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co ., to Board of Directors
Nov 5 2013 Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
Nov 1 2013 KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Oct 31 2013 Venaxis to Provide Third Quarter 2013 Business Update
Oct 31 2013 Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
Oct 28 2013 Accera, Inc. Announces Publication of Results in the Journal Neuropsychiatric Disease and Treatment of a Retrospective Cohort Study Examining the Effects of Axona in Patients With Mild-to-Moderate Alzheimer's Disease
Oct 23 2013 KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
Oct 21 2013 Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
Oct 21 2013 Aratana Therapeutics names Wendy Yarno to its Board of Directors
Oct 16 2013 Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker as President and CEO
Oct 14 2013 Aratana Agrees to Acquire Vet Therapeutics, Inc.
Oct 2 2013 Regado Biosciences, Inc. to Present at BIO Investor Forum
Oct 1 2013 Pearson’s Quotient® ADHD Test Shown to Detect “ADHD Fakers”
Oct 1 2013 Aratana Therapeutics Added to Russell Indexes
Sept 30 2013 Enteris BioPharma and Nordic BioScience’s KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris’ Proprietary Oral Drug Delivery and Manufacturing Platform
Sept 26 2013 Venaxis’ APPY1™ Test Passes Final Futility Analysis in Pivotal Clinical Study
Sept 25 2013 BioAxone BioSciences Inc. Announces Publication of Cethrin Spinal Cord Injury Clinical Trial Analysis of Treatment Outcomes in the Journal of Neurotrauma
Sept 25 2013 KemPharm 's KP201 Demonstrates Bioequivalence Compared to Norco(R) in Key Pivotal Clinical Study
Sept 25 2013 Regado Biosciences, Inc . to Present at Aegis Capital Vegas Healthcare Conference
Sept 18 2013 Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
Sept 17 2013 Regado Biosciences, Inc . Enrolls First Patient in Phase 3 Trial of REG1
Sept 11 2013 Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
Sept 10 2013 Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer's Disease Progression
Sept 6 2013 Regado Biosciences, Inc . Announces Exercise of Over-Allotment Option
Sept 5 2013 Aratana Therapeutics to Present at Two Upcoming Investor Conferences
Sept 5 2013 Venaxis to Present at Three Upcoming Investor Conferences
Sept 4 2013 Identification of a Tau Oligomer Structure That is Toxic to Neurons Published in the International Journal of Cell Biology
Sept 4 2013 KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
Sept 3 2013 Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
Sept 3 2013 Viralytics Full Year Financial Results
Aug 29 2013 Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
Aug 28 2013 KemPharm’s KP201 to be Featured at PAINWeek 2013
Aug 26 2013 KemPharm’s KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Aug 22 2013 Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Aug 20 2013 Enteris BioPharma Appoints Timothy J. Saxon, Vice President of
Business Development, to Expand “Peptelligence™ Partnering” Program
Aug 12 2013 Aratana Therapeutics Reports Second Quarter 2013 Financial Results
Aug 8 2013 Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
Aug 7 2013 KemPharm, Inc . Receives Additional Notice of Allowance for Novel Prodrugs of Hydrocodone
Aug 5 2013 Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
July 29 2013 Viralytics Advances CAVATAK™ Clinical Programs in Late Stage Melanoma, Prostate, Breast and Colorectal Cancers
July 23 2013 Aratana Therapeutics to Report Second Quarter 2013 Financial Results
July 15 2013 KemPharm, Inc . Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
July 15 2013 Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
July 15 2013 Oligomerix, Inc . Announces Addition of Industry Veteran James Hendrix, Ph.D., to Serve as Senior Director of Chemistry
July 11 2013 Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
July 8 2013 Oligomerix, Inc. to Present Multiple Posters Highlighting its Tau-Focused Technology During the Annual Alzheimer's Association International Conference®
June 27 2013 Aratana Therapeutics, Inc. Announces Pricing of Initial Public Offering
June 13 2013 JAMA Pediatrics Study Highlights Cancer Risk Associated with CT Scans
June 11 2013 KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
June 4 2013 KemPharm’s KP201 Featured at the International Conference on Opioids
May 30 2013 Venaxis Closes Underwritten Public Offering, Including Full Over-Allotment
May 23 2013 Venaxis Announces Pricing of Offering of Common Stock and Warrants
May 22 2013 Oligomerix, Inc. Completes Series B Financing
May 1 2013 ATL1102 for Multiple Sclerosis - Toxicology Study to commence (Antisense Therapeutics)
Apr 29 2013 Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Apr 18 2013 Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
Apr 16 2013 Ikaria® To Present At 2013 Bio Business Forum and International Convention
Apr 16 2013 KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
Apr 9 2013 Accera and University of Miami Announce Collaboration to Study Axona® for Cognitive Impairment in Patients with Multiple Sclerosis
Apr 8 2013 Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization
Apr 4 2013 VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
Apr 3 2013 KemPharm, Inc . Receives Notice of Allowance for Novel Pain Drug Candidate, KP201
Apr 2 2013 Lithera Receives Patent from the USPTO Protecting Methods of Use and Formulations for LIPO-202
Mar 28, 2013 SCL Health System & Univita Establish Joint Venture to Ensure Patient-Centered Care
Mar 26, 2013 Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
Mar 25, 2013 Aratana Therapeutics Adds To Drug Development Team
Mar 22, 2013 VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
Mar 20, 2013 Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
Mar 19, 2013 Venaxis to Provide Fourth Quarter 2012 Business Update
Mar 18, 2013 Venaxis Secures Additional European Commercial Development Agreements for APPY1
Mar 12, 2013 Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
Mar 11, 2013 Venaxis to Present at 25th Annual ROTH Conference
Mar 7, 2013 Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
Mar 5, 2013 Tarix Pharmaceuticals’ Peptide Technology Stimulates Revascularization Following Ischemia
Feb 14, 2013 KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
Feb 13, 2013 Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
Feb 13, 2013 Unigene Receives 2013 Drug Delivery Partnerships Industry Achievement Award
Feb 12, 2013 Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
Feb 11, 2013 Saladax Biomedical Laboratories to Offer the Full Portfolio of MyCare™ Therapeutic Dose Management Assays in the United States
Feb 7, 2013 Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
Feb 4, 2013 Venaxis, Inc. to Webcast Live at RetailInvestorConferences.com on February 7, 2013
Jan 31, 2013 Unigene Completes Financial Statement Amendment
Jan 31, 2013 Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
Jan 29, 2013 Aetna and Univita Health Work Together to Help Reduce Hospital Readmissions for Medicare Advantage Members
Jan 24, 2013 Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
Jan 23, 2013 Venaxis to Present at 2013 BIO CEO and Investor Conference
Jan 15, 2013 Aratana Therapeutics Expands Senior Management Team with Appointment of Julia A. Stephanus as Chief Commercial Officer
Jan 15, 2013 Venaxis Initiates Patient Enrollment for APPY1 Pivotal Study
Jan 15, 2013 Unigene Welcomes FDA Advisory Committee Review of Salmon Calcitonin
Jan 14, 2013 Micro Interventional Devices, Inc. Closes First Tranche of $5 Million Series B Financing
Jan 7, 2013 KemPharm, Inc Receives USAN Approval for Nonproprietary Name of Novel Pain Drug Candidate, KP201
Jan 7, 2013 Venaxis Obtains CE Mark for APPY1 Appendicitis Test
Jan 4, 2013 Univita Health to Present at 31st Annual J.P. Morgan Healthcare Conference
Jan 2, 2013 Aratana Therapeutics to Present at Biotech Showcase 2013
Jan 2, 2013 Venaxis, Inc. to Present at Biotech Showcase 2013
Dec 21, 2012 Venaxis Files for CE Mark and Prepares for European Commercialization
Dec 20, 2012 Venaxis Board Appoints Senior Diagnostics Executive to Board of Directors
Dec 19, 2012 Regado Biosciences, Inc. Secures $51 Million Series E Financing
Dec 12, 2012 Venaxis, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option
Dec 12, 2012 AspenBio Pharma Changes Company Name to Venaxis, Inc.
Dec 12, 2012 Unigene’s Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Dec 11, 2012 Unigene Engages Financial Advisor to Explore Strategic Options and Advance Corporate Objectives.
Dec 11, 2012 Univita Expands its Transition Care Program Nationally to Reduce Hospital Readmissions
Dec 7, 2012 Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
Dec 6, 2012 Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory as Part of the Company’s Commercialization Strategy
Dec 5, 2012 Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter Into Global Licensing Agreement.
Dec 5, 2012 Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY.
Nov 27, 2012 Unigene and Tarix Pharmaceuticals Definitive Licensing Agreement for “Peptelligence-Engineered” TXA127.
Nov 26, 2012 Accera Announces Initiation of Clinical Trial for AC-1204
Nov 20, 2012 Unigene Announces Third Quarter 2012 Corporate Update
Nov 20, 2012 AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock.
Nov 19, 2012 Aratana Therapeutics To Participate In Leerink Swann’s November Management Access Days.
Nov 16, 2012 Saladax Biomedical, Inc. Appoints Mark D. Myslinksi as Chief Commercial Officer
Nov 16, 2012 Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012.
Nov 14, 2012 AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock.
Nov 14, 2012 AspenBio Pharma Announces Proposed Public Offering
Nov 13, 2012 FDA Clears INOMAX® DSIR To Connect with Hospital Health Information Systems
Nov 13, 2012 AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference.
Nov 13, 2012  AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial
Nov 6, 2012 AspenBio Engages European-based Sales and Marketing Veteran Miquel Vernet to Consult on European Commercialization.
Nov 5, 2012 AspenBio Pharma to Provide Third Quarter 2012 Business Update
Oct 24, 2012 Accera, Inc.  Expands Senior Management Team to Advance Clinical Studies & Commercialization for Axona
Oct 23, 2012 Aratana Therapeutics Appoints Robert “Rip” Gerber to Board of Directors
Oct 22, 2012 Micro Interventional Devices, Inc. Initiates “First- in- Man” Clinical Study of Permaseal™
Oct 16, 2012 Unigene’s Licensee, Tarsa Therapeutics, Reports Positive Clinical Data in Phase 2 Study of Oral Calcitonin for Prevention of Postmenopausal Osteoporosis.
Oct 15, 2012 Unigene’s Oral PTH Program Featured at ASBMR 2012 Annual Meeting.
Oct 15, 2012 AspenBio Proposes Corporate Name Change to Venaxis, Inc.
Oct 4, 2012 Aratana Therapeutics Appoints Jay Lichter, PhD, Board Chairman, Welcomes MPM Capital Managing Director, John Vander Vort, JD, To Board of Directors
Oct 1, 2012 Coyote Pharmaceuticals Targets Amyotrophic lateral Sclerosis (ALS) and Alzheimer’s disease with Lead Therapeutic CNS-102
Sep 27, 2012 Aratana Therapeutics Appoints Louise Mawhinney Chief Financial Officer
Sep 27, 2012 AspenBio Plans to Initiate Pivotal Study in Fourth Quarter
Sep 26, 2012 Accera, Inc. to Support the Alzheimer’s Foundation of America’s (AFA) National Memory Screening Day (NMSD)
Sep 26, 2012 Unigene to Target Partnering and Therapeutic Development Opportunities Following Victory Park Capital Debt Financing and Forbearance.
Sep 25, 2012 AspenBio to Provide Investors with Clinical and Business Update
Sep 20, 2012 AspenBio to Present at 2012 Aegis Healthcare Conference
Sep 20, 2012 Unigene to Present at the 2012 Obesity Society’s 30th Annual Scientific Meeting.
Sep 19, 2012 Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of “Peptelligence- Engineered” TXA127.
Sep 18, 2012 AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U.S. District Court
Sep 17, 2012 BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston
Sep 13, 2012 Accera, Inc. to Present at the Biopharm America 2012 Partnering Conference in Boston, MA
Sep 12, 2012 Regado Biosciences, Inc. To Present at the UBS Global Life Sciences Conference 2012 in New York, NY.
Sep 12, 2012 Saladax Biomedical, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York City
Sep 12, 2012 Aratana Therapeutics Appoints Co-Founder and Director Steven St. Peter, MD, As President and Chief Executive Officer.
Sep 6, 2012 Saladax Biomedical, Inc. Expands Distribution of Mycare™ Products in Israel
Sep 4, 2012 AspenBio to Present at Rodman & Renshaw Annual Global Investment Conference